BR0309277A - Processo para preparação de um composto - Google Patents

Processo para preparação de um composto

Info

Publication number
BR0309277A
BR0309277A BR0309277-1A BR0309277A BR0309277A BR 0309277 A BR0309277 A BR 0309277A BR 0309277 A BR0309277 A BR 0309277A BR 0309277 A BR0309277 A BR 0309277A
Authority
BR
Brazil
Prior art keywords
compound
preparing
useful
ethoxy3
neurokinin
Prior art date
Application number
BR0309277-1A
Other languages
English (en)
Inventor
Mark Huffman
Mahmoud S Kaba
Joseph F Payack
David Hands
Original Assignee
Merck & Co Inc
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, Merck Sharp & Dohme filed Critical Merck & Co Inc
Publication of BR0309277A publication Critical patent/BR0309277A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

"PROCESSO PARA PREPARAçãO DE UM COMPOSTO". A presente invenção diz respeito a um novo processo para a preparação do composto 5-[[2(R)-[1(R)-[3,5-bis(trifluorometil)fenil]etóxi3(S)-(4-fluorofenil)-4-morf olinil]metil]-1,2-diidro-3H-1,2,4-triazol-3-ona. Este composto é útil como um antagonista de receptor (neuroquinina-1) de substância P. Em particular, o composto é útil, por exemplo, no tratamento de desordens psiquiátricas, doenças inflamatórias e êmeses.
BR0309277-1A 2002-04-18 2003-04-17 Processo para preparação de um composto BR0309277A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37373402P 2002-04-18 2002-04-18
PCT/US2003/011956 WO2003089429A1 (en) 2002-04-18 2003-04-17 Process for 5-[[2(r)-[1(r)-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3(s)-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3h-1,2,4-triazol-3-one

Publications (1)

Publication Number Publication Date
BR0309277A true BR0309277A (pt) 2005-02-22

Family

ID=29251070

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0309277-1A BR0309277A (pt) 2002-04-18 2003-04-17 Processo para preparação de um composto

Country Status (21)

Country Link
US (1) US7847095B2 (pt)
EP (1) EP1499611B1 (pt)
JP (1) JP4271586B2 (pt)
KR (1) KR100982901B1 (pt)
CN (1) CN1293077C (pt)
AR (1) AR039625A1 (pt)
AU (1) AU2003228578B2 (pt)
BR (1) BR0309277A (pt)
CA (1) CA2482466C (pt)
EG (1) EG24127A (pt)
HR (1) HRP20040974A2 (pt)
IL (1) IL164586A (pt)
MX (1) MXPA04010182A (pt)
NO (1) NO330362B1 (pt)
NZ (1) NZ535883A (pt)
PL (1) PL217076B1 (pt)
RU (1) RU2326879C2 (pt)
TW (1) TWI341313B (pt)
UA (1) UA84399C2 (pt)
WO (1) WO2003089429A1 (pt)
ZA (1) ZA200408193B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0400850D0 (sv) * 2004-03-30 2004-03-31 Astrazeneca Ab Novel Compounds
EP2266980A1 (en) 2005-10-05 2010-12-29 Ranbaxy Laboratories Limited Polymorphic form of aprepitant intermediate
EP1942734A4 (en) * 2005-10-06 2010-04-07 Reddys Lab Ltd Dr PREPARATION OF THE APREPITANT
EP1984359A1 (en) * 2006-02-03 2008-10-29 Glenmark Pharmaceuticals Limited Amorphous and crystalline forms of aprepitant and processes for the preparation thereof
WO2008026216A2 (en) * 2006-08-28 2008-03-06 Hetero Drugs Limited Process for purification of aprepitant
US8940890B2 (en) 2010-05-24 2015-01-27 Chengdu Di'ao Pharmaceutical Group Co., Ltd. Preparation method of 5-[[2(R)-[1(R)-[3,5-bis(trifluoromethyl) phenyl]ethoxy]-3(S)-4-fluorophenyl-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazole-3-one
HUP1000325A2 (en) * 2010-06-18 2012-01-30 Druggability Technologies Ip Holdco Jersey Ltd Nanostructured aprepitant compositions and process for their preparation
WO2012146692A1 (en) 2011-04-29 2012-11-01 Sandoz Ag Novel intermediates for the preparation of highly pure aprepitant or fosaprepitant
CN103030668B (zh) * 2011-10-09 2016-06-15 江苏豪森药业集团有限公司 一种制备福沙匹坦二甲葡胺的方法
PL2817305T3 (pl) * 2012-02-23 2017-06-30 Piramal Enterprises Limited Udoskonalony sposób wytwarzania aprepitantu
CZ304770B6 (cs) * 2012-03-13 2014-10-08 Zentiva, K.S. Způsob výroby 3-(((2R,3S)-2-((R)-1-(3,5-bis(trifluormethyl)fenyl)ethoxy)-3-(4-fluorfenyl)morfolino)methyl)-1H-1,2,4-triazol-5(4H)-onu (Aprepitantu) v polymorfní formě II
ITMI20130273A1 (it) * 2013-02-26 2014-08-27 Olon Spa Procedimento per la preparazione di aprepitant
CN103288813A (zh) * 2013-06-04 2013-09-11 四川百利药业有限责任公司 一种阿瑞匹坦的制备方法
CN107954998B (zh) * 2016-10-14 2022-08-12 江苏豪森药业集团有限公司 福沙匹坦中间体的制备方法
CN106967057A (zh) * 2017-06-01 2017-07-21 四川制药制剂有限公司 一种阿瑞匹坦高效制备工艺

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719147A (en) 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
US5637699A (en) 1992-06-29 1997-06-10 Merck & Co., Inc. Process for preparing morpholine tachykinin receptor antagonists
IL111960A (en) * 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
GB9513972D0 (en) * 1995-07-08 1995-09-06 Merck Sharp & Dohme Pharmaceutical compositions
ZA985765B (en) 1997-07-02 1999-08-04 Merck & Co Inc Polymorphic form of a tachykinin receptor antagonist.
GB9813025D0 (en) 1998-06-16 1998-08-12 Merck Sharp & Dohme Chemical synthesis

Also Published As

Publication number Publication date
NO20045001L (no) 2004-11-17
NO330362B1 (no) 2011-04-04
US20050215786A1 (en) 2005-09-29
IL164586A (en) 2010-11-30
EP1499611B1 (en) 2015-02-11
IL164586A0 (en) 2005-12-18
HRP20040974A2 (en) 2005-06-30
AU2003228578A1 (en) 2003-11-03
RU2004133678A (ru) 2005-05-27
CA2482466A1 (en) 2003-10-30
TW200400189A (en) 2004-01-01
UA84399C2 (en) 2008-10-27
AU2003228578B2 (en) 2009-07-30
JP2005529881A (ja) 2005-10-06
KR20050007299A (ko) 2005-01-17
RU2326879C2 (ru) 2008-06-20
CN1646525A (zh) 2005-07-27
WO2003089429A1 (en) 2003-10-30
EP1499611A1 (en) 2005-01-26
AR039625A1 (es) 2005-03-02
JP4271586B2 (ja) 2009-06-03
PL373348A1 (en) 2005-08-22
ZA200408193B (en) 2006-06-28
KR100982901B1 (ko) 2010-09-20
TWI341313B (en) 2011-05-01
CA2482466C (en) 2012-11-20
CN1293077C (zh) 2007-01-03
US7847095B2 (en) 2010-12-07
PL217076B1 (pl) 2014-06-30
EP1499611A4 (en) 2006-05-03
NZ535883A (en) 2007-12-21
MXPA04010182A (es) 2005-02-03
EG24127A (en) 2008-07-08

Similar Documents

Publication Publication Date Title
BR0309277A (pt) Processo para preparação de um composto
BR0214786A (pt) Composições nanoparticulada e farmacêutica, e, métodos para a antagonização do efeito de substância p em seu sìtio receptor ou para o bloqueio de receptores de neurocinina-1 em um paciente, para o tratamento de depressão em um paciente, para o tratamento ou a prevenção de ansiedade em um paciente e para o tratamento ou a prevenção de êmese em um paciente
BRPI0517989A (pt) processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo, e, composto ou um sal do mesmo
ATE381542T1 (de) Nr1h4-kern-rezeptor-bindende verbindungen
NO20084853L (no) Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni
PE20090160A1 (es) COMPUESTOS AMINO-5-[4-(DIFLUOROMETOXI)FENIL SUSTITUIDO]-5-FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA
BR122012009489B8 (pt) processo para produzir 2-etóxi-1-{[2’-(5-oxo-4,5-diidro-1,2,4-oxadiazol-3-il)bifenil-4-il]metil}-1h-benzimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metila ou um sal do mesmo, composição farmacéutica, e, uso
EE200300403A (et) N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina
HRP20110781T1 (hr) Derivati azabiciklo[3.1.0]heksana, korisni kao modulatori dopaminskih receptora d3
MA27781A1 (fr) 3-fluoro-piperidines comme antagonistes de nmda/nr2b.
NO20062256L (no) Hydroksyalkylsubstituerte pyrido-7-pyrimidin-7-oner
DE602004018386D1 (de) Verfahren zur herstellung von 4-(2-dipropylaminoethyl)-1,3-dihydro-2h-indol-2-on-hydrochlorid
NO20075022L (no) (7-(2-(4-(3-trifluormetylfenyl)-1,2,3,6-tetrahydropyrid-1-yl)etyl) isokinolinbesylatsalt, fremstilling og terapeutiske anvendelser derav
IL183373A0 (en) 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
MXPA05011270A (es) Compuestos de imidazopiridina que tienen actividad agonista del receptor 5-ht4 y actividad antagonista del receptor 5-ht3.
PE20110433A1 (es) Antagonistas de la via hedgehog de ftalazina disustituida
NO20085271L (no) Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni
AR022019A1 (es) Un compuesto de imidazol y las composiciones farmaceuticas que lo contienen
PE20030718A1 (es) Lactamas como antagonistas de taquiquininas
PE20080143A1 (es) Compuestos 2-oxo-3-fenil-(1,4-diazaespiro[4.5]dec-3-en-1-il)acetamida sustituidos como inhibidores del transportador de glicina
MA33166B1 (fr) Utilisation de dérivés de pyrimidylaminobenzamide pour le traitement de la fibrose
PE20050587A1 (es) Derivados de diazindol-dicarbonilo-piperazinilo como agentes antivirales
MX2010012421A (es) 5-[5-[2-(3,5-bis(trifluormetil)fenil)-2-metilpropanoilmetilamino] -4-(4-fluoro-2-metilfenil)]-2-piridinil-2-alquil-prolinamida como antagosnistas del receptor de neurocinina 1.
DE60221813D1 (de) Thiazolopyrimidinderivate und deren verwendung als antagonisten des cx3cr1 rezeptors
KR960704878A (ko) 광학 활성 이미다졸리딘온 유도체 및 이의 제조방법 (Optically active imidazolidinone derivative and process for producing the same)

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: C07D 413/06, A61P 25/00

Ipc: C07D 413/06 (2011.01)

B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME LIMITED (GB) , MERCK SHARP A

Free format text: NOME ALTERADO DE: MERCK AND CO., INC.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: MERCK SHARP AND DOHME LIMITED (GB) , SCHERING CORP

B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME LIMITED (GB) , MERCK SHARP A

B25G Requested change of headquarter approved

Owner name: MERCK SHARP AND DOHME LIMITED (GB) , MERCK SHARP A

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.